Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
daraxonrasib · 4 trials · 20 indications
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator.
OS is defined as the time from randomization until death from any cause.
DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by BICR.
OS is defined as the time from randomization until death from any cause.
Number of patients with AEs as assessed by CTCAE v5.
Number of patients with changes in vital signs.
Number of patients with changes in clinical laboratory test values.
Number of patients with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Arm A: daraxonrasib | EXPERIMENTAL | study drug |
| Arm B: daraxonrasib + gemcitabine and nab-paclitaxel | EXPERIMENTAL | study drug in combination with chemotherapy |
| Arm C: gemcitabine and nab-paclitaxel | ACTIVE_COMPARATOR | SOC chemotherapy |
| daraxonrasib | EXPERIMENTAL | study drug |
| SOC Observation | NO_INTERVENTION | Patients randomized to the comparator control arm will receive SOC observation. |
| docetaxel | ACTIVE_COMPARATOR | Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy. |
| Arm A: Daraxonrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion (+ Carboplatin/Cisplatin + Pemetrexed) |
| Arm B: Elironrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin/Cisplatin + Pemetrexed). |
| Arm C: Zoldonrasib + Ivonescimab Combination | EXPERIMENTAL | Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab). |
| Name | Type | Description |
|---|---|---|
| daraxonrasib | DRUG | oral tablets |
| gemcitabine | DRUG | intravenous (IV) infusion |
| nab-paclitaxel | DRUG | IV infusion |
| docetaxel | DRUG | intravenous (IV) infusion |
| Elironrasib | DRUG | oral tablets |
| Zoldonrasib | DRUG | oral tablets |
| Ivonescimab | DRUG | IV infusion |
| Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | DRUG | IV infusion |
| cetuximab (Cohort C2 Only) | DRUG | IV infusion |
| Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | DRUG | IV infusion |
| Daraxonrasib (Cohort B1 only) | DRUG | oral tablets |
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent. * Do...
Top 20 of 73 competitors